The Valley Desk

Clinical trial reportLung cancer (Amsterdam, Netherlands)Published

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Lung cancer (Amsterdam, Netherlands)
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Disease Progression; Carboplatin; Antineoplastic Combined Chemotherapy Protocols; Mutagenesis, Insertional; Mutation; Exons; Quality of Life; Adult; Aged
PubMed ID
41671629
Added to directory
Source checked

Report a correction or request removal